Pan Qingqing, Yang Huaxia, Zhou Ziyue, Li Min, Jiang Xu, Li Fang, Luo Yaping, Li Mengtao
Department of Nuclear Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, No.1 Shuaifuyuan Wangfujing, Dongcheng District, Beijing, 100730, China.
Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, 100730, China.
EJNMMI Res. 2024 Jan 4;14(1):2. doi: 10.1186/s13550-023-01064-4.
The identification of biomarkers predicting the treatment response of rheumatoid arthritis (RA) is important. [ Ga]Ga-FAPI-04 showed markedly increased uptake in the joints of patients with RA. The purpose of this study is to investigate whether [ Ga]Ga-FAPI-04 PET/CT can be a predictor of treatment response in RA.
Nineteen patients diagnosed with RA in the prospective cohort study were finally enrolled. Both total synovitis uptake (TSU) and metabolic synovitis volume (MSV) in [ Ga]Ga-FAPI-04 and [F]FDG PET/CT of the responders were significantly higher than those in non-responders according to Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) response criteria at 3-months' follow-up (P < 0.05). The PET joint count (PJC) detected in [ Ga]Ga-FAPI-04 and [F]FDG PET/CT were also significantly higher in CDAI responders than non-responders (P = 0.016 and 0.045, respectively). The clinical characteristics of disease activity at baseline did not show significant difference between the responders and non-responders, except CRP (P = 0.035 and 0.033 in CDAI and SDAI response criteria, respectively). The baseline PJC, TSU and MSV > cutoff values in [ Ga]Ga-FAPI-04 PET/CT successfully discriminated CDAI and SDAI responders and non-responders at 3-months' follow-up.
[ Ga]Ga-FAPI-04 uptake at baseline were significantly higher in early responders than those in non-responders. Trial registration ClinicalTrials. NCT04514614. Registered 13 August 2020, https://register.
gov/prs/app/action/SelectProtocol?sid=S000A4PN&selectaction=Edit&uid=U0001JRW&ts=2&cx=-x9t7cp.
识别预测类风湿关节炎（RA）治疗反应的生物标志物很重要。[镓]Ga-FAPI-04在RA患者关节中的摄取明显增加。本研究的目的是调查[镓]Ga-FAPI-04 PET/CT是否可作为RA治疗反应的预测指标。
前瞻性队列研究中最终纳入了19例诊断为RA的患者。根据3个月随访时的临床疾病活动指数（CDAI）和简化疾病活动指数（SDAI）反应标准，[镓]Ga-FAPI-04和[氟]FDG PET/CT中反应者的总滑膜炎摄取（TSU）和代谢性滑膜炎体积（MSV）均显著高于无反应者（P<0.05）。CDAI反应者在[镓]Ga-FAPI-04和[氟]FDG PET/CT中检测到的PET关节计数（PJC）也显著高于无反应者（分别为P = 0.016和0.045）。除CRP外，反应者和无反应者在基线时疾病活动的临床特征未显示出显著差异（CDAI和SDAI反应标准中分别为P = 0.035和0.033）。[镓]Ga-FAPI-04 PET/CT中基线PJC、TSU和MSV>临界值成功区分了3个月随访时的CDAI和SDAI反应者与无反应者。
早期反应者基线时[镓]Ga-FAPI-04摄取显著高于无反应者。试验注册ClinicalTrials.NCT04514614。于2020年8月13日注册，https://register.CLINICALTRIALS:gov/prs/app/action/SelectProtocol?sid=S000A4PN&selectaction=Edit&uid=U0001JRW&ts=2&cx=-x9t7cp。
